grant
In vivo assessment and optimization of phage PK/PD for the treatment of pulmonary Mycobacterium abscessus infection
Organization COLORADO STATE UNIVERSITYLocation FORT COLLINS, UNITED STATESPosted 11 Mar 2024Deadline 31 Jan 2029
NIHUS FederalResearch GrantFY2025AddressAmikacinAmikinAmiklinAmukinAnsamycinAntibiotic AgentsAntibiotic Drug CombinationsAntibiotic DrugsAntibiotic TherapyAntibiotic TreatmentAntibioticsBacteriaBacterial InfectionsBacteriophagesBiclinBiklinBronchiectasisCOPDChronic Obstruction Pulmonary DiseaseChronic Obstructive Lung DiseaseChronic Obstructive Pulmonary DiseaseClinicClinicalCombined AntibioticsCombined Modality TherapyCystic FibrosisDataDiseaseDisorderDoseDrug KineticsDrug TherapyDrug resistanceDrug resistant bacteriumDrugsDysfunctionEncapsulatedEnvironmentExhibitsFormulationFunctional disorderIn VitroIndividualInfectionIntravenousKnowledgeLiposomalLiposomesLung DiseasesLung infectionsM abscessusM. abscessusMacrophageMammalian CellMedicationMiceMice MammalsMiscellaneous AntibioticModelingMucoviscidosisMultimodal TherapyMultimodal TreatmentMurineMusMycobacterial InfectionMycobacterium InfectionsMycobacterium abscessusMycobacteroides abscessusMycobutinMφOutcomePK/PDPathologyPersonsPhagesPharmaceutical PreparationsPharmacodynamicsPharmacokineticsPharmacological TreatmentPharmacologyPharmacotherapyPhysiopathologyPre-Clinical ModelPreclinical ModelsPulmonary DiseasesPulmonary DisorderRegimenRespiratory physiologyRifabutinRifabutin/MicrobutinRouteSystemTherapeutic UsesTimeTranslationsVirusbacteria infectionbacterial diseasebacterial disease treatmentbacterial infectious disease treatmentbacterial virusbactericidalbactericidechronic obstructive pulmonary disordercombination therapycombined modality treatmentcombined treatmentdesigndesigningdisease of the lungdisorder of the lungdrug interventiondrug resistantdrug resistant bacteriadrug treatmentdrug/agentimprovedin silicoin vivoinsightliposomal formulationliposomal preparationlung disorderlung functionmouse modelmulti-modal therapymulti-modal treatmentmurine modelnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnon-tuberculosis mycobacterianon-tuberculosis mycobacterialnon-tuberculous mycobacterianon-tuberculous mycobacterialnontuberculosis mycobacterialnontuberculous mycobacterianontuberculous mycobacterialnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapypathophysiologypharmaceutical interventionpharmacokinetics and pharmacodynamicspharmacological interventionpharmacological therapypharmacology interventionpharmacology treatmentpharmacotherapeuticspulmonarypulmonary functionpulmonary infectionsresistance to Drugresistant to Drugrespiratory functionsmall moleculetherapeutic outcometherapy outcometranslation
Description preview
Nontuberculous mycobacteria (NTM) are environmental bacteria that cause serious pulmonary
infections in people with underlying lung diseases. One of the most common NTMs associated
with pulmonary disease is Mycobacterium abscessus (Mabs). Mabs is highly drug resistant, and
it is the most difficult NTM to treat. The therapeutic use of bacteriophage…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click